Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone
Purpose of this non-interventional study is the documentation of efficacy and safety data of multiple myeloma therapy with a combined treatment of Lenalidomide and Dexamethasone in daily routine practice.
Multiple Myeloma
Time to progression (TTP), maximum 3 years per Patient
Overall Response Rate, maximum 3 years per Patient|Time to Treatment Discontinuation (TTD), maximum 3 years per Patient|Overall Survival (OS), maximum 3 years per Patient|Safety Profile, maximum 3 years per Patient|Dosage of Lenalidomide and Dexamethasone, maximum 3 years per Patient|Kidney Function, maximum 3 years per Patient|Neutropenia / Infection (Concomitant Medication), maximum 3 years per Patient|Thrombosis Prophylaxis, maximum 3 years per Patient
Purpose of this non-interventional study is the documentation of efficacy and safety data of multiple myeloma therapy with a combined treatment of Lenalidomide and Dexamethasone in daily routine practice.